Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

著者: Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel, Regina Herbst, Dominik Wolf‎, Claudia D. Baldus, Uta Oelschlägel, Anke Mütherig, Lars Fransecky, Richard Noppeney, Gesine Bug, Katharina S. Götze, Alwin Krämer, Tilmann Bochtler, Matthias Stelljes, Christoph Groth, Antje Schubert, Marika Mende, Friedrich Stölzel, Christine Borkmann, Anne Sophie Kubasch, Malte von Bonin, Hubert Serve, Mathias Hänel, Ulrich Dührsen, Johannes Schetelig, Christoph Röllig, Michael Krämer, Gerhard Ehninger, Martin Bornhäuser, Christian Thiede - The Lancet 2018 被引用: 354